EYEPOINT PHARMACEUTICALS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.04 USD | -2.64% |
|
-8.43% | -30.66% |
| Apr. 02 | EyePoint Pharmaceuticals, Inc. Expands Scientific Advisory Board | CI |
| Mar. 18 | EyePoint Pharmaceuticals, Inc.(NasdaqGM:EYPT) added to S&P Pharmaceuticals Select Industry Index | CI |
Financials (USD)
| Sales 2024 * | 47.06M | Sales 2025 * | 17.36M | Capitalization | 821M |
|---|---|---|---|---|---|
| Net income 2024 * | -79M | Net income 2025 * | -144M | EV / Sales 2024 * | 12.9 x |
| Net cash position 2024 * | 215M | Net cash position 2025 * | 348M | EV / Sales 2025 * | 27.2 x |
| P/E ratio 2024 * |
-10.7
x | P/E ratio 2025 * |
-6.31
x | Employees | 121 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.79% |
More Fundamentals
* Assessed data
More news
Latest transcript on EyePoint Pharmaceuticals, Inc.
More recommendations
More press releases
| 1 day | -6.26% | ||
| 1 week | -21.35% | ||
| Current month | -20.32% | ||
| 1 month | -26.01% | ||
| 3 months | -31.20% | ||
| 6 months | +122.87% | ||
| Current year | -28.73% |
1 week
16.22
18.68
1 month
16.2223.65
Current year
16.2230.99
1 year
5.6730.99
3 years
2.1930.99
5 years
2.1930.99
10 years
2.1958.10
| Managers | Title | Age | Since |
|---|---|---|---|
Jay Duker
CEO | Chief Executive Officer | 66 | 16-09-26 |
George Elston
DFI | Director of Finance/CFO | 59 | 19-11-13 |
Said Saim
CTO | Chief Tech/Sci/R&D Officer | 66 | 19-06-09 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jay Duker
CEO | Chief Executive Officer | 66 | 16-09-26 |
Wendy DiCicco
BRD | Director/Board Member | 56 | 19-07-14 |
David Guyer
BRD | Director/Board Member | 64 | 19-01-24 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.84% | 11 M€ | -6.03% | - | |
| 0.37% | 4 M€ | -5.15% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 16.07 | -2.43% | 79 024 |
| 24-04-24 | 16.47 | -6.26% | 1,178,938 |
| 24-04-23 | 17.57 | +3.66% | 942,987 |
| 24-04-22 | 16.95 | -3.97% | 1,386,877 |
| 24-04-19 | 17.65 | +0.86% | 1,548,446 |
Delayed Quote Nasdaq, April 24, 2024 at 04:00 pm EDT
More quotes
EyePoint Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the business of developing and commercializing ophthalmic products for the treatment of eye diseases. The Company's pipeline leverages its Durasert technology (Durasert) for sustained intraocular drug delivery, including delivery of EYP-1901, is an investigational sustained delivery treatment for anti-vascular endothelial growth factor (anti-VEGF) mediated retinal diseases. Its additional pipeline programs include EYP-2301, a promising TIE-2 agonist, razuprotafib, formulated in Durasert E to potentially improve outcomes in serious retinal diseases. EYP-1901 is presently in Phase 2 clinical trials as a sustained delivery treatment for wet age-related macular degeneration (wet AMD), no proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The Companyâs other products include YUTIQ, and DEXYCU.
Sector
Pharmaceuticals
Calendar
2024-04-30
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
16.47
USD
Average target price
43.89
USD
Spread / Average Target
+166.48%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -28.73% | 821M | |
| +25.61% | 660B | |
| +25.87% | 562B | |
| -5.24% | 358B | |
| +16.49% | 322B | |
| +8.28% | 297B | |
| +7.09% | 219B | |
| -9.12% | 196B | |
| +5.01% | 199B | |
| -8.75% | 149B |
- Stock Market
- Equities
- EYPT Stock
